RESUMO
Patients with leukocyte adhesion deficiency type 1 (LAD1) suffer from life-threatening bacterial infections due to mutations in the common ß2 integrin subunit (CD18/ITGB2 gene). We tested different fragments of the ubiquitous chromatin opening element (UCOE) from the human HNRPA2B1-CBX3 locus for their efficiency in driving the human CD18 gene expression and compared it with that of an elongation factor 1 alpha promoter (EF1αL, 1169â¯bp; EF1αS 248â¯bp) and a murine stem cell virus (MSCV) promoter within the context of the same lentiviral vector backbone. These vectors were tested in vitro for the human CD18 gene expression on the surface of CD34+ hematopoietic stem cells (HSCs) isolated from both moderate and severe LAD1 patients. Among the promoters tested in the patients' CD34+ HSCs, only U631â¯bp, U652â¯bp, U1262â¯bp, 5' 2.2â¯kb A2UCOE and EF1αS resulted in higher percentage of CD18+CD34+ cells comparable to that of the MSCV promoter. The U655â¯bp, U723â¯bp, U1296â¯bp, U2598â¯bp and EF1αL promoters resulted in comparatively lower numbers of CD18+CD34+ cells. This study would be useful in investigating the human CD18 gene expression in an ex vivo experiment to demonstrate the phenotypic correction of LAD1 in a pre-clinical model.
Assuntos
Antígenos CD18/genética , Proteínas Cromossômicas não Histona/genética , Ribonucleoproteínas Nucleares Heterogêneas Grupo A-B/genética , Lentivirus/genética , Síndrome da Aderência Leucocítica Deficitária/genética , Fator 1 de Elongação de Peptídeos/genética , Terapia Genética , Vetores Genéticos/genética , Células HEK293 , Células-Tronco Hematopoéticas/metabolismo , Humanos , Síndrome da Aderência Leucocítica Deficitária/terapia , Regiões Promotoras Genéticas , Elementos Reguladores de Transcrição , Transdução GenéticaRESUMO
Gene therapy refers to the treatment of genetic diseases using normal copies of the defective genes. It has the potential to cure any genetic disease with long-lasting therapeutic benefits. It remained an enigma for a long period of time, which was followed by a series of setbacks in the late 1990s. Gene therapy has re-emerged as a therapeutic option with reports of success from recent clinical studies. The United States and Europe has been pioneers in this field for over two decades. Recently, reports of gene therapy have started coming in from Asian countries like China, Japan and Korea. This review focuses on the current status of gene therapy in India.
